Docket Number:12A-920716, 12A-920716B, 12A-920716C, 12A-920716D
Inventor:Yuan-Tsong Chen, Shuen-Iu Hung, Wen-Hung Chung, Jer-Yuarn Wu
IP Status:Issued TWI287580、US7,470,513B2、US7,964,351B2、US8,012,686、AU2004289951、CA2,544,369、EP1697539B1、IN253258、PH1-2006-500916、SG12232、ZL200480040177.91、US9,562,268
Abstract:
This invention encompasses the discovery of two specific genetic markers that can be used for identifying individuals at risk to develop SJS/TEN to certain drugs.
Fields of Application:
Big Pharma is gearing up for practical pharmacogenomics by measuring human genetic variations and using them to predict drug responses or adverse drug reactions. The genetic markers described in the Invention can be used in identifying individuals who are at risk for a serious drug-induced adverse reaction, SJS/TEN. Such screening can be done prior to drug prescription to decrease serious adverse effects or for improving the successful rate of drug development by including these variant alleles in their "pharmacogenomics profile" or by excluding high-risk subjects in the clinical trial.
Advantages when compared to the existing technologies:
None of the current method/technology has sufficient predictive value to be clinically useful for risk assessment for patients who might develop drug-induced SJS/TEN.
Contact Person:Mei-Fang Lee / 886-2-2787-2503 / mflee@gate.sinica.edu.tw
